Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?
Zacks Investment Research | Jul 29, 2019 09:23PM ET
Invitae Corporation (NYSE:NVTA) is scheduled to report second-quarter fiscal 2019 results on Aug 6, 2019, after market close.
In the first quarter of 2019, the company’s loss per share of 47 cents was wider than the Zacks Consensus Estimate by 2.2%. However, the company delivered a positive earnings surprise in three of the trailing four quarters, the average beat being 5.7%.
Let’s take a look at how things are shaping up prior to this announcement.
Factors at Play
Over the last few quarters, genetic testing, one of Invitae’s key business segments, has been consistently delivering robust performance.
Lately, the company has been witnessing a rise in the number of oncology patients undergoing genetic testing.In the last reported quarter, the company accessioned more than 94,000 samples for genetic testing, which reflected a 47% year-over-year increase. This trend is expected to have continued in the second quarter.
Invitae Corporation Price and EPS Surprise
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.